External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Dermatology Pemphigus Vulgaris

Pemphigus Vulgaris

Pemphigus vulgaris (PV) is a rare, life-threatening and often misdiagnosed autoimmune disease.

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Nov 11 / Roche and Genentech
HCP Interview: Experience on the treatment of PV patients and recent clinical trial data
In this interview, a prominent expert in pemphigus share his experience on the treatment of PV patients and recent clinical trial data.
Dermatology Pemphigus Vulgaris EADV-2019

Sign up or login to unlock the full suite of MEDICALLY features
Nov 11 / Roche and Genentech
PV Patient Interview Part 1: From first symptoms to diagnosis
In this patient interview, a patient with pemphigus vulgaris (PV) provides tangible insights on the PV patient journey from first symptoms to diagnosis.
Dermatology Pemphigus Vulgaris EADV-2019

Sign up or login to unlock the full suite of MEDICALLY features
Nov 11 / Roche and Genentech
PV Patient Interview Part 2: Burden of disease and treatment
In this patient interview, a patient with pemphigus vulgaris (PV) provide tangible insights on the PV patient burden of disease and treatment.
Dermatology Pemphigus Vulgaris EADV-2019

Sign up or login to unlock the full suite of MEDICALLY features
Nov 11 / Roche and Genentech
HCP Interview: Experience on the diagnostic and treatment journey of PV patients
In this interview, a prominent expert in pemphigus share her experience on the diagnostic and treatment journey of her PV patients.
Dermatology Pemphigus Vulgaris EADV-2019

Sign up or login to unlock the full suite of MEDICALLY features
Oct 9 / Roche and Genentech
Long-term effectiveness and safety of rituximab for the treatment of pemphigus in Chinese population
Data of rituximab (RTX) therapy for pemphigus in Chinese population were scarce; the study aimed to assess the long-term effects and safety of RTX for the treatment of pemphigus in clinical practice.
Dermatology Pemphigus Vulgaris EADV-2019
Upcoming Congresses
Access to Roche and Genentech's latest medical information
View related congresses

Disease Education

About Pemphigus Vulgaris

Stay up to date with the latest information about pemphigus vulgaris and learn more about this autoimmune disease

Learn more
Open asset
Share page

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.